ProStrakan on course for strong full-year results
This article was originally published in Scrip
Executive Summary
ProStrakan continued to beat analysts' expectations in the first 10 months of this year, with a 33% increase in revenue. Its pan-European products Tostran, Rectogesic and Xomolix performed particularly well, growing by 72%, of which the strong euro accounted for 22%.